Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041532 | 0.85 | CA12 (0.46) | CTSDCA12CA1CA2CA7 | |
| SCHEMBL8321013 | 0.84 | CTSD (0.41) | CTSDCA12CA1CA2CA7 | |
| SCHEMBL9728468 | 0.83 | PPARG (0.48) | CTSDCYSLTR2CYSLTR1PPARGPPARD | |
| SCHEMBL9062684 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7PDK2 | |
| SCHEMBL4016040 | 0.77 | PPARG (0.41) | CA12CA1CA2CA7PDK2 | |
| SCHEMBL8922421 | 0.77 | PRKCI (0.53) | CA12CA1CA2CA7PDK2 | |
| SCHEMBL19126030 | 0.77 | PRKCI (0.42) | CYSLTR2CYSLTR1CA12CA1CA2 | |
| SCHEMBL28879796 | 0.76 | CA12 (0.42) | CA12CA1CA2CA7PDK2 | |
| SCHEMBL8578774 | 0.76 | ALDH1A1 (0.39) | CA12CA1CA2CA7PDK2 | |
| SCHEMBL6274458 | 0.75 | ALDH1A1 (0.51) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300041-B2 | Liquid oral simvastatin compositions | ROSEMONT PHARMACEUTICALS LTD (GB) | 2019-05-28 | — | — | US | disclosed |
| US-20170143669-A1 | LIQUID ORAL COMPOSITIONS | ROSEMONT PHARMACEUTICALS LTD. (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9597289-B2 | Liquid oral simvastatin compositions | ROSEMONT PHARMACEUTICALS LTD. (GB) | 2017-03-21 | — | — | US | disclosed |
| US-20090311330-A1 | LIQUID ORAL COMPOSITIONS | ROSEMONT PHARMACEUTICALS LTD. (GB) | 2009-12-17 | — | — | US | disclosed |
| EP-2018153-A1 | LIQUID ORAL COMPOSITIONS | Rosemont Pharmaceuticals Ltd (GB) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007125339-A1 | LIQUID ORAL COMPOSITIONS | ROSEMONT PHARMACEUTICALS LTD (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311330-A1 | LIQUID ORAL COMPOSITIONS | HMGCR, LIPA, PCSK9 | CTSD 2652/4885CYSLTR2 1611/4885CYSLTR1 1697/4885 |
| US-10300041-B2 | Liquid oral simvastatin compositions | APOB, HMGCR, PROC | CTSD 2434/4885CYSLTR2 3500/4885CYSLTR1 2801/4885 |
| US-20170143669-A1 | LIQUID ORAL COMPOSITIONS | HMGCR, APOB, PROC | CTSD 2441/4885CYSLTR2 3301/4885CYSLTR1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.